Infusystem Holdings, Inc (INFU) Stock Price & Analysis
Infusystem Holdings, Inc (INFU) rose 0.00% to USD 9.01 as of June 10, 2026 at 04:57 UTC, according to Nexqual real-time market data.
INFU last closed at USD 9.01; the session ranged USD 8.85–9.11 on volume of 150,056 shares. Market capitalization is $181.84M, with a 52-week range of USD 5.38–11.04 (ASE). Source: Nexqual, June 10, 2026 at 04:57 UTC.
Key Statistics (as of June 10, 2026 at 04:57 UTC)
| Price | USD 9.01 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 9.01 |
| Open | USD 8.96 |
| Day Range | USD 8.85 – 9.11 |
| 52-Week Range | USD 5.38 – 11.04 |
| Volume | 150,056 shares |
| Market Cap | $181.84M |
| Exchange | ASE |
Technical Analysis (INFU)
Nexqual's technical model rates INFU "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:57 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.36 (neutral) |
| vs SMA50 | Below (USD 9.57) |
| MACD | -0.14 (negative) |
Analyst Ratings (INFU)
Wall Street analysts rate INFU "None" based on 4 analysts, with a mean price target of USD 14.88 (range USD 12–17.5), per Nexqual as of June 10, 2026 at 04:57 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 14.88 |
| High Target | USD 17.5 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (INFU)
| Next Earnings Date | 2026-08-04 |
|---|---|
| Revenue Estimate | $36.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.05 vs est 0.03 ▲ beat |
| 2025-12-31 | USD 0.1 vs est 0.07 ▲ beat |
| 2025-09-30 | USD 0.15 vs est 0.05 ▲ beat |
| 2025-06-30 | USD 0.15 vs est 0.04 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:57 UTC.
Financials & Fundamentals (INFU)
| Total Revenue | $142.40M |
|---|---|
| Revenue Growth (YoY) | -3.00% |
| Gross Margin | +56.75% |
| Operating Margin | +4.72% |
| Profit Margin | +5.55% |
| ROE | +13.89% |
| Debt / Equity | 41.03 |
| Current Ratio | 2.14 |
| Total Cash | $2.11M |
| Total Debt | $24.10M |
| Free Cash Flow | $17.43M |
Source: Nexqual, June 10, 2026 at 04:57 UTC.
Financial Health Score (INFU)
Nexqual rates Infusystem Holdings, Inc's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 04:57 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 57%, operating 5% |
| Balance Sheet | Strong — $2M cash vs $24M debt |
| Cash Flow | Solid — FCF $17M, 12% margin |
| Efficiency | Mixed — ROE 14%, ROA 6.7% |
Ownership (INFU)
| Insider Ownership | +7.15% |
|---|---|
| Institutional Ownership | +83.14% |
| Shares Outstanding | 20.18M |
| Float | 18.52M |
| Short % of Float | +0.86% |
Source: Nexqual, June 10, 2026 at 04:57 UTC.
Leadership (INFU)
Infusystem Holdings, Inc is led by Carrie A. Lachance B.S.N., M.B.A., R.N. (age 48), President, CEO & Director, per Nexqual as of June 10, 2026 at 04:57 UTC.
| President, CEO & Director | Carrie A. Lachance B.S.N., M.B.A., R.N. (age 48) |
|---|---|
| Executive VP & CFO | Barry G. Steele (age 54) |
Major Backers & Investors (INFU)
Notable institutional backers of Infusystem Holdings, Inc include First Eagle Investment Management, LLC, Minerva Advisors LLC, American Century Companies Inc, according to Nexqual as of June 10, 2026 at 04:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Eagle Investment Management, LLC | 6.82% |
| Minerva Advisors LLC | 5.97% |
| American Century Companies Inc | 4.71% |
| Punch & Associates Investment Management, Inc. | 4.15% |
| Acadian Asset Management. LLC | 3.14% |
| Renaissance Technologies | 2.81% |
| Heartland Advisors Inc. | 2.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.4% |
| BlackRock | 3.06% |
| Dimensional Fund Advisors | 2.94% |
Source: Nexqual, June 10, 2026 at 04:57 UTC.
From Infusystem Holdings, Inc's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada.
- It operates through two segments: Patient Services and Device Solutions.
- The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
- It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELMD | Electromed, Inc. | USD 36.29 | ▼ 3.71% |
| IRIX | IRIDEX Corporation | USD 1.12 | ▲ 2.75% |
| JYNT | The Joint Corp. | USD 8.41 | ▲ 1.45% |
| MLSS | Milestone Scientific, Inc. | USD 0.39 | ▼ 8.1% |
| KRMD | KORU Medical Systems, Inc. | USD 4 | ▲ 1.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:57 UTC. This page is informational and not investment advice.